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Current antibiotics, derived mainly from natural sources, inhibit a narrow spectrum of cellular processes,
namely DNA replication, protein synthesis, and cell wall biosynthesis. With the worldwide explosion of
drug resistance, there is renewed interest in the investigation of alternate essential cellular processes,
including bacterial central metabolic pathways, as a drug target space for the next generation of antibiotics.
However, the validation of targets in central metabolism is more complex, as essentiality of such targets can
be conditional and/or contextual. Bearing in mind our enhanced understanding of prokaryotic central meta-
bolism, a key question arises: can central metabolism be bacteria’s Achilles’ heel and a therapeutic target for
the development of new classes of antibiotics? In this review, we draw lessons from oncology and attempt
to address some of the open questions related to feasibility of targeting bacterial central metabolism as a
strategy for developing new antibacterial drugs.In recent years, the dramatic rise inmicrobial drug resistance has
led organizations such as the Infectious Diseases Society of
America and the World Health Organization to warn of a ‘‘post-
antibiotic era’’ when pathogenic microbes will be recalcitrant
to the current antibacterial regimens (Alanis, 2005; Boucher
et al., 2009; Raviglione, 2006). Indeed, some totally drug-resis-
tant pathogenic bacteria have already eroded earlier advances
in treatment and control (Rowland, 2012).
Existing antimicrobial drugs have been identified from
phenotypic screens on the basis of their ability to kill bacteria
or inhibit their growth. They act by inhibiting a limited spectrum
of cellular processes essential during logarithmic growth,
namely biosynthesis of proteins, RNA, DNA, cell wall, and folic
acid. Although there is continued success in finding inhibitors
against such targets (Bax et al., 2010; Makarov et al., 2009;
Phillips et al., 2011), the frequency is low and dwindling
remarkably compared with the ‘‘golden era’’ of antibiotic drug
discovery (Fischbach and Walsh, 2009; Payne et al., 2007).
Furthermore, pathogenic bacteria have developed sophisti-
cated intrinsic drug resistance mechanisms that are hard wired
in the microbial metagenome as a natural phenomenon and are
difficult to fight (Bhullar et al., 2012; D’Costa et al., 2011, 2006).
Given the current gap between our ability to develop novel an-
tibiotics and the pressing need for drugs active against drug-
resistant and drug-tolerant populations (a nonheritable form
of ‘‘resistance’’ or tolerance to antibiotic stress; a subpopula-
tion of microbes insensitive to antibiotics concentrations that
are otherwise cidal to the majority of the clonal population),
there is motivation to consider alternative essential cellular pro-
cesses as a target space for the development of antibacterial
classes.
Bacterial pathogens respond to specific nutritional cues
within the host microenvironment. Microbial pathogenicity isChemistry & Biology 2dictated by virulence factors that are required to establish
infection at a given site and by metabolic pathways required
to support growth (Brown et al., 2008). The host can in fact
be considered as ‘‘a growth medium’’ that is exploited by mi-
crobial pathogens to multiply and cause diseases (Brown
et al., 2008; Garber, 1960). Restricting access to essential nutri-
ents is an integral part of innate immunity, a concept that
was originally proposed by Louis Pasteur. To establish infec-
tion, bacterial pathogens reprogram their metabolic network,
balancing biosynthetic processes with sufficient ATP biogen-
esis to support both growth and survival (Eisenreich et al.,
2010; Liu et al., 2012; Schnappinger et al., 2003; Stavru et al.,
2011). These altered metabolic pathways are absolutely essen-
tial for survival in vivo and represent an appealing space to
expand the repertoire of antimicrobial drug targets. Historically,
central metabolism has been considered unattractive for devel-
oping antimicrobials because of the possible lack of selectivity
since most metabolic enzymes are conserved from bacteria
to human. Nevertheless, it is important to remember that
most clinically used antibiotics also target conserved cellular
processes.
Success in targeting bacterial central metabolism will emerge
from understanding of precisely how cells regulate the flux of
nutrients into pathways that are essential for biosynthesis and
energy metabolism under relevant growth conditions (Figure 1).
Such an understanding necessitates the use of methods to un-
tangle metabolic flux and pathway regulation that are not often
used inmainstream drug discovery (Munger et al., 2008; Rabino-
witz et al., 2011). Herein we review recent findings that support
the therapeutic value of targeting bacterial central metabolism,
examine the associated challenges, and outline a framework
for targeting this niche. We focus our attention on intermediary
carbon metabolism, drawing lessons from oncology and other1, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1423
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Figure 1. Interactions between Molecular
Components Give Rise to Metabolic
Network Responses
(A) Complexity arises through multiple overlapping
regulatory mechanisms and metabolic feedback
(black dotted arrows) in the components that
mediate the primary flow of genetic information
(gray arrows). Gene expression acts only on
enzyme abundance, posttranslational modifica-
tion may modulate abundance and kinetic pa-
rameters. Allosteric regulation exclusively modu-
lates the kinetic parameters through noncovalent
binding of effector molecules to noncatalytic sites.
(B) The actual in vivo reaction rate (i.e., metabolic
flux in the cell) also depends on the reactant con-
centrations. Accordingly, metabolic fluxes are the
net sums of underlying enzymatic reaction rates,
which are an integral output of four physiologic
elements interacting at the level of enzyme kinetics
(protein abundance, kinetic parameters, metabo-
lite concentrations, and metabolite thermody-
namics). Bacterial infection alters the metabolic
flux of host cells through certain parts of the
metabolic network. In addition, the metabolic flux
of the bacteria is different in vivo compared to the
axenic cultures.
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has delivered preclinical and clinical drug candidates (Tennant
et al., 2010; Vander Heiden, 2011).
Targeting Metabolism: Lessons from Oncology and Viral
Diseases
The therapeutic potential of actively shifting the metabolic flux
from one pathway to another has recently been shown in
the modulation of the oncogenic mammalian pyruvate kinase
(PYK) isoform 2 (M2PYK), a hallmark for cancer metabolism
(Vander Heiden et al., 2009; Ward and Thompson, 2012). Onco-
genic cells have preeminent rates of glucose uptake and yet the
rates of mitochondrial oxidative phosphorylation remain un-
changed, a phenomenon known as aerobic glycolysis or the
Warburg effect.
Among the four PYK isoforms found in humans (Yamada and
Noguchi, 1999), M2PYK plays a key role in cancer metabolism
(Christofk et al., 2008). In an elegant approach to target the regu-
lation of M2PYK activity, a switch in PYK expression to M1PYK
isoform, an isoform expressed in healthy cells, lead to the
reversal of the Warburg effect and reduction in tumor prolifera-
tion in nude mouse exenografts (Anastasiou et al., 2011; Chris-
tofk et al., 2008). To further validate the therapeutic potential of
this approach, Anastasiou et al. (2012) analyzed the effect of1424 Chemistry & Biology 21, November 20, 2014 ª2014 Elsevier Ltd All rights reservedconstitutively modulating M2PYK to a
highly active tetrameric state on tumor
cell glycolysis. Treatment of tumor cells
with a M2PYK activator depleted the
glucose-derived carbon intermediates
and suppressed the flux of carbon into
oncogenic biosynthetic pathways, (Anas-
tasiou et al., 2011; Christofk et al., 2008),
leading to reduced tumorigenic prolifera-
tion both in vitro and tumor mouse
models. Therefore, the bottleneck at the
PYK level of an otherwise hyperactivemetabolic pathway enables the flux redirection of glucose-
derived carbons into anabolic pathways supporting macromo-
lecular synthesis of cell proliferation building blocks (Anastasiou
et al., 2011; Mazurek, 2011) (Figure 2). This result is an elegant
example of knowledge-based modulation of disease meta-
bolism by manipulating the metabolic flux as a therapeutic
intervention that could be adapted to the development of novel
antibacterial agents.
In infectious diseases, an insightful understanding of meta-
bolic flux induced by enveloped viruses recently revealed
numerous metabolic processes important for viral replication
in vivo as targets for antiviral therapy (Munger et al., 2006,
2008; Vastag et al., 2011) (Figure 3). Infection by these viruses
induces nucleotide biosynthesis, central carbon and lipid meta-
bolism closely resembling the hallmarks of cancer metabolism
such as anaerobic glycolysis (the Warburg effect) and elevated
flux from glucose metabolism into both nucleotide biosynthesis
and fatty acid metabolism. Using fatty acid biosynthesis inhib-
itors, Munger et al. (2008) chemically validated the suppression
of viral replication during human cytomegalovirus (HCMV)
infection, demonstrating the significance of increased flux
through the tricarboxylic acid cycle and its efflux into fatty acids
biosynthesis during infection (Munger et al., 2008). By quanti-
fying the integrated network response to infection, an antiviral
Figure 2. M2PYK in Cancer Metabolism: A Metabolic Bottleneck on
Glycolysis and Its Effects on the Pentose Phosphate Pathway
(A) Pyruvate kinase isoform M2 (M2PYK) is present in very few types of
proliferating normal cells but is present at high levels in cancer cells. M2PYK
catalyzes the rate-limiting step of glycolysis, controlling the conversion of
phosphoenolpyruvate (PEP) to pyruvate and thus ATP generation.
(B) Although counterintuitive, M2PYK antagonizes the Warburg effect by in-
hibiting glycolysis and the generation of ATP in tumors. M2PYK provides an
advantage to cancer cells because, by slowing glycolysis, this isozyme allows
carbohydrate metabolites to enter other subsidiary pathways, including the
hexosamine pathway, uridine diphosphate-glucose synthesis, glycerol syn-
thesis, and the pentose phosphate pathway (PPP), which are required for
macromolecule biosynthesis and the maintenance of redox balance that is
needed to support the rapid cell division. ATP, adenosine triphosphate; G6P,
glucose-6-phosphate; PEP, phosphoenolpyruvate. Red lines with bars denote
the constrained flux byM2PYK. Red pathways indicate the flux of carbons and
their ‘‘overflow’’ into biosynthetic pathways supporting cancer proliferation by
M2PYK.
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proteins and envelopes, could be rationally identified. Such a
remodeling of central carbon metabolism in both viruses and
oncogenic cells is reminiscent of carbon storage in nongrowing
but metabolically active (NGMA) bacteria (Rittershaus et al.,
2013), a subpopulation known to be refractory to current anti-
bacterials.Chemistry & Biology 2Approved Antimicrobials Targeting Central Metabolism
The development of selective antibacterials targeting central
metabolism has historical precedent. A classical archetype is
the development of drugs inhibiting the folate pathway (Bushby
and Hitchings, 1968; Lombardo et al., 2004; Shah et al., 2004;
van Miert, 1994). Folate is an essential cofactor required for
many one-carbon transfer reactions and is a critical precursor
for the biosynthesis of purines, pyrimidines, and amino acids.
Dihydrofolate reductase (DHFR) plays a central role in maintain-
ing cellular pools of tetrahydrofolate, a precursor for the synthe-
sis of glycine, methionine, thymidine triphosphate, and purines.
Inhibition of DHFR activity depletes the cell of essential metab-
olites for protein, RNA, and DNA biosynthesis, resulting in bac-
terial stasis (Bushby and Hitchings, 1968; Kwon et al., 2010;
van Miert, 1994). Although both humans and bacteria encode
a functional DHFR, trimethoprim (TMP) selectively inhibits
many microbial DHFRs because of the bacterial specific coop-
erative binding properties of DHFR, DFHR-cofactor nicotin-
amide adenine dinucleotide phosphate, and TMP (Baccanari
and Kuyper, 1993; Kwon et al., 2010). The high safety and effi-
cacy of TMP reside in its selective inhibition of bacterial DHFRs,
with an affinity of TMP several orders of magnitude higher for mi-
crobial DHFR compared with the human counterpart (Baccanari
and Kuyper, 1993; Birdsall et al., 1983; Hitchings and Burchall,
2006).
Another clinical drug target in the folic acid biosynthetic
pathway is dihydropteroate synthase (DHPS), the target of the
first synthetic antimicrobial agent Prontosil (Domagk, 1935).
DHPS catalyzes the condensation of r-aminobenzoic acid
(rABA) with 7,8-dihydropterin-pyrophosphate to form 7,8-dihy-
dropteroate, a key convergent step in the pathway. Sulfanil-
mide drugs are structural analogs and competitive inhibitors
of rABA at the DHPS active site. Like TMP, the inhibition of
DHPS critically depletes cellular folate levels inducing thymine-
less death (Then and Angehrn, 1973). Today, DHFR-DHPS in-
hibitor combinations continue to be used as a first-line therapy
in the prophylaxis and treatment of HIV-associated secondary
pneumocystis carinii pneumonia infections. Recent studies
have revealed that r-aminosalicylic acid (PAS), a second-line
anti-TB drug that has been clinically used for more than 60
years, inhibits the folate pathway by a unique mode of action.
Instead of acting as a DHPS inhibitor as suggested from its
chemical structure, PAS is in fact recognized as a substrate
mimic of rABA and is bioactivated by DHPS into the antimetab-
olite hydroxyl-dihydrofolate that subsequently poisons folate-
metabolic dependent pathways (Chakraborty et al., 2013;
Zheng et al., 2013).
The ability to develop bacterial selective inhibitors on enzymes
involved in central metabolism has further been recently exem-
plified by the development of bedaquiline for the treatment of
tuberculosis. Bedaquiline is an antitubercular drug targeting
the F0F1 ATP synthase (Andries et al., 2005; Koul et al., 2007).
In spite of the evolutionary conservation between mycobacteria
and human, the mycobacterial ATP synthase is at least 20,000
times more sensitive to bedaquiline than human mitochondrial
ATP synthase (Haagsma et al., 2009). Taken together, these
landmark antimicrobials stimulate interest in exploring pathways
whose sequence and architecture is similar to their human
homologs.1, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1425
Figure 3. Hijacking Host Cell Metabolism:
Central Carbon Metabolism during a Viral
Infection
Viruses (hepatitis C virus, herpes simplex virus
[HSV] human influenza virus, HCMV) hijack host
cell metabolism during infection by rerouting
central carbon metabolism toward macromole-
cule biosynthesis pathways—fatty acid biosyn-
thesis and nucleotide biosynthesis—to support
the biosynthesis of viral subunits. HSV infection
specifically increases flux from glycolysis to de
novo pyrimidine biosynthesis via glucose ana-
plerotic pathway pyruvate carboxylase, and
aspartate transaminases. In line with these flux
routes, small interfering RNA knockdowns of
the glucose anaplerotic pathway way pyruvate
carboxylase and aspartate transaminase-2
impaired HSV replication, demonstrating potential
antiviral targets emerging from central meta-
bolism. Red pathways show major flux changes
following viral infection. Areas of potential inhibi-
tion are depicted in blue lines with bars on top.
AcCoA, acetyl coenzyme A; DHAP, dihydroxyac-
etone phosphate; G6P, glucose-6-phosphate;
Mal-CoA, Malonly-CoA.
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Historically, ideal drug targets have been genes whose function
is important for growth or survival under a chosen condition, so-
called essentiality (the demonstration that the abrogation of
function of a specific gene/gene product results in the loss of
bacterial viability [or phenotypic alteration] that is sufficient to
affect bacterial survival either in vitro or in vivo), and are
amenable to chemical inhibition, a property commonly referred
to as druggability (the likelihood of being able to modulate the
function of a target with a druglike small molecule, usually esti-
mated by classifying it with known gene families that have previ-
ously been successfully targeted with drugs). The increase in the
wealth of information on functional genes required for growth
and survival under different disease relevant conditions (Becker
et al., 2006; Sassetti and Rubin, 2002) led to the concept of a
minimal genome. Such a functional requirement for growth has
been used to prioritize potential drug targets (Hasan et al.,
2006; Payne et al., 2007). Genetic essentiality to validate a
drug target falls short of evaluating the vulnerability (a measure
of the minimum inhibition threshold limiting bacterial growth
and mimicking the gene null phenotype; such an indicator de-
fines whether a proposed drug target requires partial or com-
plete inhibition and can be used to rationally prioritize drug
targets for whole-cell and pathway based phenotypic screens)
of the target to partial inhibition, which mimics the chemical1426 Chemistry & Biology 21, November 20, 2014 ª2014 Elsevier Ltd All rights reservedinactivation by a drug (Wei et al., 2011).
Such a validation is even more significant
for central metabolic enzymes where
the intracellular substrate concentrations
of the metabolites are higher or close
to the KM of the respective catalyzing
enzyme (Bennett et al., 2009).
The integration of chemistry and
biology expertise has redefined the
criteria for target validation in drug dis-
covery. The ‘‘essentiality’’-driven target
validation failed to separate the attributesof a well-validated target, as evaluated pharmacologically by
distinguishing it from the biological properties of a vulnerable
pathway, whose impairment abrogates growth under disease
relevant conditions. Deciphering this property is critical and
carries discrete, yet overlapping, information of both biology
and chemistry. Chemical validation of proposed essential tar-
gets is imperative because, unlike gene inactivation that
completely abolishes activity, it enables the quantification of
the minimal inhibition threshold required to mimic the gene null
phenotype (in the cell, the drug will seldom exhibit 100% target
occupancy). Conditional expression of essential genes enables
the titration of the gene product to quantify such a threshold
(Gandotra et al., 2007; Woong Park et al., 2011; Zhang et al.,
2000). In a compendium, such chemically validated essential tar-
gets can be ranked to prioritize drug targets for early stage drug
discovery (Yin et al., 2004), thus ensuring the maximum resource
allocation to the most vulnerable drug targets. The utility of hy-
persensitized strains has been repeatedly documented as a plat-
form to generate new leads from phenotypic screens (DeVito
et al., 2002; Phillips et al., 2011;Wang et al., 2006), even for path-
ways that have been recalcitrant to inhibition to date (Abrahams
et al., 2012; Barry et al., 2009; Mak et al., 2012). The use of a
pathway-sensitive screen in hypoxic conditions to identify novel
ATP depleting antimycobacterials that are active on both active
and NGMAmycobacteria demonstrates the power of these tools
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sentiality of metabolic targets is often conditional and/or contex-
tual, it is important to highlight that most methodologies used to
identify antibacterial drug candidates do not reproduce any rele-
vant conditions relevant for infection in vivo. This is a serious
bottleneck that is starting to be appreciated (Fahnoe et al.,
2012; Pethe et al., 2013; Stanley et al., 2014; Zlitni et al., 2013)
and taken into consideration at the discovery and assay devel-
opment stage.
Current Platform and Approaches to Identify Inhibitors
of Metabolic Targets
The germ theory by Luis Pasteur described the body as a culture
vessel (Pasteur, 1878). More than a culture vessel, the human
body is a chemostat where essential nutrients important for mi-
crobial growth are continually replenished to enable establish-
ment, maintenance of infection, and development of disease
(Brown et al., 2008; Garber, 1960). Accordingly, the impediment
of any step between establishment and maintenance of Myco-
bacterium tuberculosis (M. tuberculosis) infection can result in
loss of virulence (Dick et al., 2010; Gouzy et al., 2013; Mun˜oz-
Elı´as andMcKinney, 2006;Woong Park et al., 2011) or resistance
of the host to infection (Walburger et al., 2004; Zhang et al.,
2013). As a result, the interest in further understanding themicro-
environment where microbes reside during infection has opened
up potential avenues for chemotherapy (Marrero et al., 2010;
Munger et al., 2006, 2008; Mun˜oz-Elı´as and McKinney, 2005;
Puckett et al., 2014).
A converging finding from many of these studies is the poor
predictive value of in vitro culture conditions used to study mi-
crobial physiology and to evaluate drug candidates (Brinster
et al., 2009; Pethe et al., 2010; Brown et al., 2008; Garber,
1960). Accordingly, the need to develop predictive assay condi-
tions has seen the emergence of new alternative protocols to
identify central metabolic inhibitors (Fahnoe et al., 2012; Pethe
et al., 2013; Stanley et al., 2014; Zlitni et al., 2013). A central
feature in all these phenotypic assays is the use of minimal me-
dia, devoid of the replete nutrients in the standard broth. Acces-
sibility tomost nutrients per se ismore difficult from the host than
in nutrient rich media; thus, if there is need to use a ‘‘default cul-
ture medium’’ for phenotypic screening, it should be defined and
minimal at best in order to chemically probe the totality of the
biosynthetic pathways. For instance, the presence of vitamins
or amino acids in M. tuberculosis whole cell-based screens
should be avoided since they usually cannot be acquired from
the host (Beste et al., 2013, Dick et al., 2010; Gouzy et al.,
2013, 2014, Tullius et al., 2003). Nevertheless, the precise
composition of the culture broth medium remains to be estab-
lished for most pathogenic bacteria. Likewise, the amount of
metals such as iron, copper, or zinc must be adapted to reflect
physiological concentration in target organs or cellular compart-
ment (Corbin et al., 2008; Samanovic et al., 2012; Schaible and
Kaufmann, 2004). The inventive identification of inhibitors target-
ing glycine and biotin biosynthetic pathways in E. coli growing on
minimal media using metabolomics illustrates the utility of
nutrient limitation in early stage drug discovery (Zlitni et al.,
2013). The platform presented in this study is promising to iden-
tify additional small-molecule inhibitors of essential metabolism
pathways and should be easily adaptable to most bacteria. InChemistry & Biology 2addition, inhibitors targeting the glyoxylate shunt (Fahnoe
et al., 2012), ATP metabolism (Mak et al., 2012), and electron
transport chain (Pethe et al., 2013), together with some whose
mechanism of action is yet to be understood but are active on
NGMA cells (Stanley et al., 2014), demonstrate the power of
screening for inhibitors using in vitro conditions mimicking at
least some key aspect of the in vivo niche the bacilli reside in.
In an elegant counter immunity screen, Zhang et al. (2013)
recently demonstrated that the mycobacterial tryptophan
biosynthetic pathway could be targeted by small-molecule inhib-
itors to promote the clearance ofM. tuberculosis in synergy with
the immune system in infected animals (Zhang et al., 2013).
These findings together with others (Gouzy et al., 2013; Lee
et al., 2013; McKinney et al., 2000) provide a proof of principle
that the metabolic pathways required for intracellular survival
in an immune-competent host can be exploited as potential tar-
gets for therapy. This kind of concept could only emerge in a
physiologically relevant system that can reproduce essential as-
pects of the host immunity. Similarly, the remarkable efficacy of
bedaquiline in treating mycobacterial infections has recently
been attributed to its enhanced bactericidal activity in nonfer-
mentable carbon sources (Koul et al., 2014). This is noteworthy
because mycobacterial populations residing in human macro-
phages and in vivo primarily utilize lipids as a source of carbon
(Lee et al., 2013; Timm et al., 2003). Fittingly, bedaquiline has
enhanced bactericidal activity in macrophages compared to its
extracellular activity (Dhillon et al., 2010). The relevance of
screening in infected macrophages (Brodin et al., 2010), a rele-
vant physiological environment for M. tuberculosis and other
pathogens, has recently led to the identification of the energy
metabolism inhibitor Q203 (Pethe et al., 2013). Interestingly,
Q203 is 10 times more potent against bacteria replicating inside
macrophages compared with classical culture broth medium.
Analogous to bedaquiline, Q203 selectively inhibits the respira-
tory cytochrome bc1 complex in mycobacteria in spite of archi-
tectural conservation of the bc1 complex in many species,
including humans (Pethe et al., 2013).
Unless a metabolic target is validated clinically, we advocate
for the use of a whole cell-based screen to identify new antibac-
terial targeting central metabolism. Indeed, target-based drug
discovery is overly reductionist in concept for two primary rea-
sons. The drug-organism relationship is reduced to drug-target
interplay without integrating the complexity of systems pharma-
cology. In addition, bacterial metabolic networks are very robust;
this enables them to maintain stable function in the face of
environmental perturbations. One of the advantages of probing
central metabolism in whole cells in a predictive culture broth
medium is a complete recapitulation of the metabolic fluxes
and compensatory or bypass system the bacteria possesses
to multiply or survive. The in vivo efficacy of bioactive inhibitors
from these screening conditions should be evaluated prior to
intensive lead optimization to clearly validate the physiological
relevance of the targeted pathway in establishing infection or
persistence.
Modulation of Bacterial Metabolic State to Kill
Phenotypic Drug-Tolerant Bacteria
In addition to bacterial drug resistance, drug tolerance and
‘‘dormancy’’ are two major causes of treatment failure for most1, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1427
Table 1. Metabolic Pathways that Impair Bacterial Growth and Drug Tolerance
Metabolic Pathway Impact References
Fatty acid anaplerosis and gluconeogenesis impairs the establishment and maintenance
of infection
Blumenthal et al., 2010; Marrero et al., 2010;
Mun˜oz-Elı´as and McKinney, 2005
Vitamin biosynthesis impairs the establishment and maintenance
of infection
Dick et al., 2010; Duckworth et al., 2011;
Woong Park et al., 2011
Respiration (ATP biosynthesis and proton
motive force)
impairs bacterial growth and promotes killing
of NGMA cells
Gengenbacher et al., 2010; Mak et al., 2012;




eliminates NGMA cells and impairs the
establishment of infection
Kim et al., 2013
Amino acid biosynthesis impairs the establishment of infection Beste et al., 2013; Gouzy et al., 2013, 2014;
Tullius et al., 2003
Proteolysis deregulation proteome degradation through Clp proteases
leading to eradication of NGMA cells
Conlon et al., 2013; Schmitt et al., 2011
Metabolite supplementation stimulate the eradication of NGMA cells by
aminoglycoside
Allison et al., 2011
Indole metabolism stationary phase signaling molecules induces
drug tolerance
Vega et al., 2012
Chemistry & Biology
Reviewserious bacterial infections. Given that most antibiotics are inept
at killing NGMA cells (Balaban et al., 2004; Rao et al., 2008) and
the innate dynamic tolerance to antibiotic stress in microbes
(Wakamoto et al., 2013), new approaches are needed to elimi-
nate these subpopulations. Actively shifting the characteristic
metabolic flux of drug-tolerant NGMA microbes toward an
actively growing state offers a fresh prospect to control such
populations. Recent studies have demonstrated that shifting
the bacterial metabolism from a quiescent to a replicating
state increases sensitivity to antibiotics. Allison et al. (2011)
demonstrated that upon addition of the metabolites mannitol
or fructose, bacterial persisters became hypersensitive to ami-
noglycosides (Allison et al., 2011). Mannitol and fructose stimu-
lated bacterial central metabolism by inducing the proton motive
force in NGMA cells, thereby enabling aminoglycoside uptake
and consequent killing.
The application of such an approach for drug discovery
was recently shown when a compound library was screened
against persistent E. coli in combination with ampicillin (Kim
et al., 2011). A polycyclic small molecule C10 accelerated the
reversion of persister cells to normal cells and potentiated
ampicillin killing (Kim et al., 2011). Although no persister spe-
cific metabolic pathway was identified for C10 potentiation,
the notion of metabolic modulation to enhance the efficacy of
current antibiotics provides key insights into the Achilles’ heel
of persistent cells. Possible future metabolic approaches for
eliminating persister cells include collapsing the proton motive
force (Allison et al., 2011; Farha et al., 2013; Rao et al., 2008),
dissipating intracellular nutrient storage in mycobacteria (Baek
et al., 2011), or inducing reactive oxygen species (ROS)
production (or inhibiting ROS-protective genes) in order to in-
crease the potency of bactericidal antibiotics (Brynildsen
et al., 2013; Grant et al., 2012) (Table 1). The application of
selective manipulation of cellular ROS regulatory systems in
aberrant cells has recently gained momentum as a therapeutic
approach in oncology (Cabello et al., 2007; Pelicano et al.,
2004; Schumacker, 2006; Trachootham et al., 2009), an initia-1428 Chemistry & Biology 21, November 20, 2014 ª2014 Elsevier Ltdtive that will probably benefit the antibacterial drug discovery
field.
Challenges and Opportunities in Targeting Central
Metabolism in Bacteria
The opportunity to develop drugs targeting central metabolic
pathways against bacteria is broad for all diseases where
metabolism is important for pathogenesis such as malaria
(Storm et al., 2014) and intrinsic pathologies such as chronic
neuropathic pain (Patti et al., 2012). Success in targeting central
metabolic pathways for bacterial pathogens will emerge from
understanding the pathophysiology in metabolism using the po-
wer of metabolomics to yield novel drug targets as demon-
strated in virology and oncology. The key challenge in targeting
central metabolism is the paucity in understanding the convo-
luted nature of metabolic networks together with how bacteria
adapt and regulate these pathways to meet their bioenergetic
demands (Figure 1A) (Heinemann and Sauer, 2010). Under-
standing how central metabolism is regulated in vivo is essential
in the development of stratified treatments against both drug-
resistant and persistent bacteria. It is also critical to understand
pathway redundancies or bypass mechanisms within a complex
metabolic pathway to envision whether it might be necessary to
block multiple points within such a network. Such an under-
standing has been key in the development of sulfonamides as
anti-infective and anticancer agents.
A recent report on bacterial metabolome analysis demon-
strated that the concentrations of metabolites in central meta-
bolism are higher or close to the KM of their consuming
enzymes (Bennett et al., 2009). This has strong implications in
flux regulation. Metabolite concentrations greater than 50% of
the enzyme KM indicate that these metabolic steps can be effi-
ciently governed by enzyme inhibition. However, such enzymes
can also be easily activated and have most of their active sites
occupied, thus compelling greater potency and longer drug resi-
dence times for molecules targeting these pathways (Copeland
et al., 2006). Alternatively, the development of antimetabolitesAll rights reserved
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circumvent this problem and thus presents an alternate
approach to discover antibacterials (Chakraborty et al., 2013;
Zheng et al., 2013). Inhibitors targeting central metabolism are
being developed within the pharmaceutical industry for many
different applications such as cancer, diabetes, and other meta-
bolic disorders (Cabello et al., 2007; Hawser et al., 2006; Peli-
cano et al., 2004; Schumacker, 2006; Trachootham et al.,
2009; Vander Heiden, 2011). In targeting bacterial central meta-
bolism, it is plausible to ‘‘piggyback’’ off the extensive platforms
from oncology and other metabolic diseases such as obesity
and hyperlipidemia. For instance, access to preexisting meta-
bolism curated libraries may allow for the extensive screening
of a vast number of compounds without the cost of time and syn-
thesis, meaning that medicinal chemistry can be devoted on the
optimization of lead compounds.
The paucity of tractable leads resulting from both phenotypic
and target based screens for antibacterials has partly been
attributed to the limited chemical diversity in the libraries
used for screening (Payne et al., 2007). This is because the li-
braries utilized were built on medicinal chemistry efforts largely
focusing on human therapeutic targets (Payne et al., 2007).
Therefore, by pursuing bacterial targets with high sequence or
structural homology to eukaryotic proteins, the full potential of
our current chemical collection could be exploited for antibac-
terial drug discovery as demonstrated by Miller et al. (2009).
Early evidence suggests that the existing collection of eukary-
otic inhibitors (for cancer and other metabolic disorders) pre-
sent in pharmaceutical libraries can be mined for their activity
against structurally related bacterial targets (Johnson et al.,
2009; Magnet et al., 2010; Miller et al., 2009; Schreiber et al.,
2009), with a focus on selectivity once a promising lead mole-
cule has been identified. Such an approach to generate novel
antibacterial agents targeting new biosynthetic processes war-
rants investigation.
Targeting metabolic enzymes also offers unique challenges
within the drug discovery process because of the low druggabil-
ity of many central metabolic enzymes (Hopkins and Groom,
2002, 2003). Their active sites are usually shallow and often
accommodate hydrophilic substrates thus; the opportunity to
build a good inhibitor is poor due to the lack of hydrophobic
patches. Nevertheless, the paradigm is changing, and interest
in these targets is growing in oncology and other metabolic
disorders (Teicher et al., 2012; Vander Heiden, 2011). Alternative
assay formats, innovative screening paradigms, and chemical
strategies remain to be developed. Many of these tools are
already in place in industry from more established fields
on cellular metabolism such as oncology or other discovery
programs targeting metabolic disorders. The transfer of this
expertise to anti-infective biology will accelerate the drug devel-
opment of new antibacterials targeting central metabolism.
In summary, targeting central metabolism in bacterial patho-
gens represents an attractive proposition in the future develop-
ment of novel antibacterial drugs. While some of these enzymes
are unique to bacteria, many of the enzymes are sufficiently
similar to allow exploitation of chemical libraries designed for
mammalian metabolic enzymes, and yet different enough to
achieve selectivity, which can be established as a new chemo-
type against bacterial infections.Chemistry & Biology 2ACKNOWLEDGMENTS
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